# Inclisiran

Drug · id `cardio:inclisiran` · Cardiovascular Atlas · release `f6f6f1b6f50379ed` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Leqvio

Browse, condition area: Coronary and vascular disease  

## In plain language

Inclisiran is an injected medicine that lowers LDL cholesterol by switching off the instructions that make the PCSK9 protein. A health professional gives it. A large outcome trial, ORION-4, has not yet reported whether it reduces heart events.

## Technical summary

RxNorm ingredient 2588243. A double-stranded small interfering RNA (siRNA) that directs breakdown of the messenger RNA for PCSK9, per the US drug label. Brand product: Leqvio. Outcomes evidence is pending: the ORION-4 registry record is active, not recruiting.

## Connected pages

- Breaks down the messenger RNA that codes for PCSK9: PCSK9 (gene and protein) (`cardio:pcsk9`)
- Files under this front: Medicines (`cardio:front-medicines`)
- Contained in: Inclisiran (Leqvio) (`cardio:leqvio`)
- Investigated in: ORION-4 (inclisiran outcome trial) (`cardio:orion-4`)

## Provenance

Content hash: 0f33685eb93d967782cf16dcbd4046dea4579a2c486fad77339ef977335d00de
Last substantive edit: 2026-10-15
Evidence last checked: 2026-10-14